Shifting focus in the therapeutics of immunobullous disease

De, Abhishek; Ansari, Asad; Sharma, Nidhi; Sarda, Aarti

doi:10.4103/ijd.ijd_199_17

Cited by 8 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab is indicated in three different diseases, namely in non-Hodgkin’s lymphoma (alone or in combinations with other drugs), chronic lymphocytic leukemia (the most common form of leukemia in adults) and rheumatoid arthritis (in cases where other treatments have been ineffective or insufficient). Rituximab is an antibody directed against the CD 20 antigen on the surface of cell B [ 28 ]. In the USA, the drug is also used in treating vulgar pemphigus, some vasculitis, and in children, it is used in treating Burkitt's lymphoma but also acute B-cell leukemia [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

“…Rituximab is an antibody directed against the CD 20 antigen on the surface of cell B [ 28 ]. In the USA, the drug is also used in treating vulgar pemphigus, some vasculitis, and in children, it is used in treating Burkitt's lymphoma but also acute B-cell leukemia [ 28 ]. Adverse effects on the ocular surface associated with Rituximab therapy include a burning sensation, excessive tearing (lacrimation), conjunctivitis, and in some instances, vision decrease or loss [ 28 - 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ocular adverse effects of anti-cancer chemotherapy

Stoicescu,

Iancu,

Popa Cherecheanu

et al. 2023

JMedLife

View full text Add to dashboard Cite

Cancer ranks as the second leading cause of mortality in Europe, following cardiovascular diseases. Every year, 2.6 million people are diagnosed with this disease, and 1.2 million die. It has an impact not only on individual health but also on society and the economy. The survival rate has improved with the introduction of new diagnostic methods and anti-cancer chemotherapy. While more aggressive chemotherapeutic regimens and combination therapies have demonstrated efficacy against cancer cells, they also have detrimental effects on normal cells, leading to systemic and ocular adverse reactions associated with cytotoxicity, inflammation, and neurotoxicity. Consequently, we have an increased survival rate, but the appearance of these ocular adverse effects decreases the quality of life. Ocular toxicity induced by chemotherapeutic agents is often underestimated. While prevention may not be possible, proper management by an ophthalmologist, an integral part of the oncology patient's medical team, is crucial. The ophthalmologist should assess the patient before initiating chemotherapeutic treatment and continue monitoring throughout to identify any adverse ocular reactions resulting from the systemic chemotherapy. This article aimed to briefly highlight the adverse reactions occurring at the ocular surface in patients undergoing chemotherapeutic treatment. Fortunately, these ocular side effects are limited only to the period in which the chemotherapeutic treatment is done, with most of them disappearing a few weeks after stopping the treatment.

show abstract

Section: Introductionmentioning

confidence: 99%